The likelihood of approval (LoA) of Chengdu Kanghong Pharmaceuticals’ (SHE:002773) Phase III conbercept in neovascular age-related macular degeneration (AMD) dropped 7 points as of 12 April, according to GlobalData’s LoA data. The drop came as the company said on 9 April the Phase III PANDA-1 (NCT03577899) trial will stop.

The statement noted that global health emergencies and changes in external environments had caused great difficulties for the clinical research as large numbers of the 1,140 patients have stopped treatment, missed follow-ups, and exceeded testing windows. The number of cases tested for the dosing regimen is now less than 40% of the enrolled cases, it said. The trial has been unable to obtain results with registrational value, it added.

The vascular endothelial growth factor (VEGF) and placental growth factor (PIGF) inhibitor had an LoA of 37% for AMD. Based on GlobalData’s analysis using a combination of machine learning and a proprietary algorithm, the LoA has dropped to 30%. Conbercept prevents VEGF and its endothelial cell surface receptor binding, blocking its biological activity and inhibiting endothelial cell proliferation and angiogenesis.

Sean Rai-Roche is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.